Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as veledimex, Activator Ligand
INXN-1001 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| INXN-1001 | DRUG | Capsules given once daily for 14 days for 3 treatment cycles. |
| INXN-3001 | BIOLOGICAL | Intratumoral injection |
Inclusion Criteria: 1. Males or females of all races ≥ 18 years of age and ≤ 75 years of age; 2. Unresectable Stage III C (in transit) or Stage IV melanoma (M1a, M1b, M1c with LDH ≤ 2x ULN), arising from primary cutaneous, mucosal, or subungual melanoma of any tumor thickness or from an unknown pri...
Top 20 of 52 competitors
INXN-1001 is an investigational small molecule developed for the treatment of melanoma, including advanced disease. It has been studied in a Phase 1 trial in subjects with Stage III or IV melanoma. It is not an approved therapy and remains in clinical development.
INXN-1001 targets mIL-12, a cytokine. By acting on this molecular target, the drug is designed to influence cytokine-mediated immune activity in the tumor setting. This mechanism underlies its evaluation as an intratumoral approach in melanoma.
INXN-1001 is being developed by Alaunos Therapeutics, Inc., which trades under the ticker TCRT. The company is the sponsor of the clinical program evaluating the agent in melanoma.
INXN-1001 is in Phase 1 development. The program includes one completed Phase 1 trial, and no active trials are ongoing. The drug is investigational and has not been approved for any indication.
INXN-1001 has been evaluated in the completed Phase 1 trial NCT00815607, titled Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma. The trial enrolled 12 participants in the United States and studied patients with melanoma.